• Partnering for success: Selecting and managing CDMOs with ADC capabilities
• Mitigating risk in sourcing high-potency payloads and linker chemistries
• Coordinating upstream biologics and small molecule manufacturing timelines
• Ensuring compliance and safety in handling and transport of cytotoxic components
• Aligning supply strategy with clinical and commercial goals for ADC programs